my understanding DT is that hormone & targeted inhibitor has the potential to be a frontline - given the 100% response results with chemotherapy they have the basis to offer this in trial as a potential frontline therapy. Offering this at first without an in human proof of concept, such as the current phase 2, in the range of 100% response in the current trial - would be difficult ethically as women have to agree to forego a ‘proven’ therapy. Have been reading a ‘Walk with Purpose’ which is written by a former biotech entrepreneur who suffered head and neck cancer moving to lung/liver. His detailed memoir includes the journey of chemotherapy as a first, immunotherapy as a second which failed and chemo as third line treatment. It extended his life - but the side effects and consequences of chemotherapy were horrendous - Gained a new appreciation of the significance of The AKT inhibitor trial testing effectiveness with lower doses of chemo in this context - Quality of life significance
PTX Price at posting:
5.8¢ Sentiment: Hold Disclosure: Held
